

Zilretta™ (triamcinolone acetonide extended-release injectable suspension)

When requesting Zilretta (triamcinolone acetonide extended-release injectable suspension), the individual requiring treatment must be diagnosed with an FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved Indication

Zilretta is indicated as an intra-articular injection for the management of osteoarthritis pain of the knee.

Coverage Guidelines

Osteoarthritis pain of the knee

The individual must meet **all** of the following criteria for approval:

- Has a diagnosis of osteoarthritis of the knee that has been confirmed by radiologic evidence (e.g. x-ray, magnetic resonance imaging, computed tomography scan, or ultrasound);
- Has not previously received Zilretta injection;
- Has had an inadequate response to previous intra-articular corticosteroid injection.

Approval duration: 1 dose

Recommended Dosing

Administer 32mg as a single intra-articular injection.

References

1. Zilretta injection [prescribing information]. Burlington, MA: Flexion Therapeutics; March 2022.
2. Betamethasone sodium phosphate and betamethasone acetate injection [prescribing information]. Shirley, NY: American Regent; June 2020.
3. Dexamethasone sodium phosphate injection [prescribing information]. Lehi, UT: Civica; November 2019.
4. Methylprednisolone acetate injection [prescribing information]. Bridgewater, NJ: Amneal; July 2021.
5. Immediate-release triamcinolone acetonide injection [prescribing information]. Bridgewater, NJ: Amneal; December 2020.
6. Kolasinski SH, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the management of osteoarthritis of the hand, hip, and knee. *Arthritis Care Res.* 2019;72(2):149-162.
7. American Academy of Orthopaedic Surgeons Management of Osteoarthritis of the Knee (NonArthroplasty) Evidence-Based Clinical Practice Guideline. Available at: <https://www.aaos.org/oak3cpq>. Accessed on April 25, 2022.